Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Center for Infection Research, 66123, Saarbrücken, Germany.
Department of Pharmacy, Saarland University, 66123, Saarbrücken, Germany.
Angew Chem Int Ed Engl. 2020 Jun 22;59(26):10292-10296. doi: 10.1002/anie.202001407. Epub 2020 May 11.
Elimination of pulmonary Pseudomonas aeruginosa (PA) infections is challenging to accomplish with antibiotic therapies, mainly due to resistance mechanisms. Quorum sensing inhibitors (QSIs) interfering with biofilm formation can thus complement antibiotics. For simultaneous and improved delivery of both active agents to the infection sites, self-assembling nanoparticles of a newly synthesized squalenyl hydrogen sulfate (SqNPs) were prepared. These nanocarriers allowed for remarkably high loading capacities of hydrophilic antibiotic tobramycin (Tob) and a novel lipophilic QSI at 30 % and circa 10 %, respectively. The drug-loaded SqNPs showed improved biofilm penetration and enhanced efficacy in relevant biological barriers (mucin/human tracheal mucus, biofilm), leading to complete eradication of PA biofilms at circa 16-fold lower Tob concentration than Tob alone. This study offers a viable therapy optimization and invigorates the research and development of QSIs for clinical use.
消除肺部绿脓假单胞菌(PA)感染是一项具有挑战性的任务,抗生素疗法主要由于耐药机制而难以实现。因此,群体感应抑制剂(QSIs)可以干扰生物膜的形成,从而补充抗生素的作用。为了将两种活性药物同时递送到感染部位,我们制备了一种新合成的鲨烯硫酸氢盐(SqNPs)的自组装纳米颗粒。这些纳米载体允许以 30%和大约 10%的比例实现亲水性抗生素妥布霉素(Tob)和新型亲脂性 QSI 的高载药量。负载药物的 SqNPs 显示出改善的生物膜穿透性,并在相关的生物屏障(粘蛋白/人气管粘液、生物膜)中增强了疗效,导致在 Tob 浓度低约 16 倍的情况下完全消除了 PA 生物膜。本研究提供了一种可行的治疗优化方案,并为 QSIs 的研究和开发提供了新的思路,以应用于临床。